ABSTRACT
Background: Published studies on the response to COVID-19 vaccination are primarily focused on hemodialysis. We studied the humoral response to the COVID-19 vaccine in a PD population over a 6 month follow-up period. Method(s): In a retrospective single-center study, we assessed response to COVID-19 vaccination in patients on PD at 4 weeks, 3 months and 6 months after completing the full vaccination series. Response was measured via semiquantitative COVID-19 spike protein total antibody (IgG) level using a chemiluminescent sandwich immunoassay. Antibody (Ab) titers <1 were categorized as no response, 1 to <20 as intermediate, and >20 as high response. Chi-squared tests for categorical variables and unadjusted linear regression for continuous variables were used to compare characteristics among responders vs non-responders. Result(s): Of 119 patients on PD who received COVID-19 vaccine as of December 2021, 108/119 (91%) had a positive Ab response and 11/119 (9%) had no response. A total of 37% had an intermediate and 53.7% had a high response. Positive COVID-19 serology prior to vaccination (p= 0.010) as well as type of vaccine (p=0.032) were associated with higher Ab response in univariate analyses. Other factors were not statistically significantly associated with Ab response. Among the 73 participants with Ab levels at all timepoints, at 4 weeks, 11 (15%) had no Ab response, 19 (26%) intermediate, and 43 (59%) high response. At 3 months, 12 (16%) of participants had no Ab response, 27 (37%) intermediate, and 34 (47%) high response. At 6 months, 12 (16%) of participants had no Ab response, 38 (52%) intermediate, and 23 (32%) high response. Conclusion(s): Most PD patients developed a positive Ab response to the COVID-19 vaccine. Positive COVID-19 serology prior to vaccination and the type of vaccine received were associated with higher Ab response. Our data suggests promising COVID-19 vaccine response among PD patients.
ABSTRACT
PT. PLN (Persero) as one of the State-Owned Enterprises (BUMN) received a mandate from the Indonesian government to provide electricity services. PLN ensures that the availability of electricity supply throughout Indonesia is currently sufficient through a power plant development program of 35 Gigawatt. On the other hand, the condition of the Covid-19 Pandemic during the New Normal period in Indonesia significantly impacted people’s behavior in Indonesia in all respects, especially in accessing public services. To provide solutions related to the high community needs in obtaining services in the electricity sector in the current new normal period, PT. PLN (Persero) has made innovations by providing alternative online service media such as the mobile-based PLN New Mobile Application and has been integrated with other PLN applications such as the Centralized Customer Service Application and the Integrated Complaints and Complaints Application as well as digital payment services. This study measures the effectiveness of the New PLN Mobile Application in improving service and satisfaction for customers in the New Normal era in Tanjung pandan City. Thus, we use four variables often used in electronically assessing service quality, namely Efficiency, Fulfilment, Service Availability, and Privacy. The method used in this study is a quantitative method with a questionnaire approach. The sampling method used is purposive sampling with the criteria of respondents who have used the New PLN Mobile application. The number of samples used was 396 respondents. Based on the analysis of the results of the questionnaire test, observation, and other supporting data, it can conclude that New PLN Mobile Application has been significantly effective because it has fulfilled all the variables mentioned above.
ABSTRACT
Background: In initial published reports of dialysis patients, response to COVID-19 vaccination tends to be lower as compared to general population. To date, these studies were primarily focused on hemodialysis (HD) patients. We studied the factors associated with COVID-19 vaccine humoral response in PD patients. Methods: Our research setting was a single-center academic institution in New York City. We included patients on PD who received the COVID-19 vaccine. Response was assessed at a median of 4 weeks after completing the full vaccination series by measuring semiquantitative COVID-19 spike protein total antibody (Ab) level using a chemiluminescent sandwich immunoassay. Chi-squared tests for categorical variables and Wilcoxon rank-sum tests for continuous variables were used to compare characteristics among patients who did and did not have an Ab response. Results: Of 111 patients on PD in our center, 64 (58%) received COVID-19 vaccine as of April 2021 and had Ab levels checked. A total of 60/64 (94%) of patients had a positive Ab response and 4/64 (6%) did not mount a response. IgG levels in positive responders were a median of 11.5 (interquartile range, 1.9 -20). Lower Kt/V was associated with a positive Ab response (p = 0.045) and type of vaccine was associated with an Ab response (p = 0.028). Age, BMI, diabetes, hypertension, lymphocyte count, or residual Kt/V were not statistically significantly associated with Ab response to the vaccine (Table 1). Conclusions: In conclusion, the vast majority of patients on PD developed positive Ab response to the COVID-19 vaccine. While a small sample size limited our statistical power, our results show promising COVID-19 vaccine effectiveness among patients on PD.